Allergic rhinitis in children (pediatric allergic rhinitis) Respiratory
Conditions
Interventions
This is a single-centre, randomised, parallel-group controlled clinical study.
Participants will be randomly in a 1:1 ratio to either the control group or the observation group using a computer-gene
Chinese NMPA approval number H20090138). The dry suspension will be dissolved in an appropriate volume of water immediately before administration. Children aged 4–10 years will receive 2.5 mg (1 sache
Chinese NMPA approval number HJ20140117). Fluticasone propionate nasal spray will be administered as 1 spray (50 µg) into each nostril once daily (total daily dose 100 µg) for 4 weeks. Before the star
Sponsors
Affiliated Huaian No. 1 People’s Hospital
Eligibility
Sex/Gender
All
Age
4 Years to 10 Years
Inclusion criteria
Inclusion criteria: 1. Met the diagnostic criteria for allergic rhinitis, presenting with symptoms such as nasal itching, clear rhinorrhea, paroxysmal sneezing, and hyposmia 2. Had not used systemic glucocorticosteroids or antihistamines within the 2 weeks prior to enrollment 3. Had complete clinical data and no history of drug allergies 4. The children and their guardians were fully informed and signed the informed consent form 5. Aged 4-10 years
Exclusion criteria
Exclusion criteria: 1. Concomitant with other nasal diseases such as asthma, nasal polyps, or severe deviated nasal septum 2. History of nasal surgery 3. Accompanied by severe primary diseases of the heart, liver, kidneys, or hematopoietic system 4. Poor adherence to prescribed medication
Countries
China
Contacts
Public ContactHu Jian
Outcome results
None listed